Wietse Tol
ID: UNCST-2021-R013085
|
AlCohol use in HumanitariAN settings: a programme of work to address alcohol use disorders and associated adversities among conflict-affected populations in UGanda and UkrainE (CHANGE)
REFNo: SS1596ES
• To identify strategies and techniques from evidence-based alcohol use therapies which can be integrated into PM+, and to develop a new intervention called PM+A (Problem Management Plus Alcohol)
• To adapt PM+A to local circumstances, and to examine the feasibility, acceptability, perceived effectiveness, and preliminary impact of PM+A
• To evaluate effectiveness and cost-effectiveness of PM+A through two single-blind randomised controlled trials in Uganda and Ukraine
• To explore the process of implementation, and to identify, characterise and explain mechanisms that promote or inhibit the delivery and take-up of PM+A in both settings
• To examine the potential for scaling-up PM+A in Uganda and Ukraine
|
Arua, Ofua zone Rhino Camp
|
Netherlands |
2023-02-17 12:18:30 |
2026-02-17 |
60 |
Adult South Sudanese men (>18 years) who meet all the following criteria.;
Alcohol Use Disorder Identification Test (AUDIT) score 8-19 (Saunders et al., 1993)
2) Elevated levels of psychological distress (Kessler Psychological Distress Scale (ten item version) (K10 >6) (Kessler et al., 2002)
|
Wellcome Trust and the Department of Health and Social Care, through the National Institute for Health Research |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
.jpg)
|
Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. Version 1.0, 22 September 2022. DAIDS study protocol ID: 38932
REFNo: HS2599ES
iii. Cohort 2: To describe the maintenance of viral suppression and immunologic activity of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),iv. Cohort 2: To describe HIV-1 genotypes and phenotypes for children who experience virologic failure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CAB LA + RPV LA (injectable only),ii. Cohort Cohort 2: To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),i. Cohort 2: To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable) and 44 weeks of CAB LA + RPV LA (injectable only),ii Cohort 1: To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oral and injectable) through Week 24,i.Cohort 1: To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable) through Week 24,
|
Kampala, all parishes
Wakiso, all parishes
|
Uganda |
2023-02-13 11:10:13 |
2026-02-13 |
90 children and 90 parents/ caregivers worldwide but MUJHU plans to enroll 5 -15 children and 5-15 parents/ caregivers. |
Children living with HIV-1, two years to less than 12 years of age
and weighing ≥10 kg and <40 kg, who are virologically suppressed on
stable antiretroviral therapy and their parents/caregivers.
|
DAIDS/NIH |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES
Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
|
Mbarara, Kamukuzi
Mbarara, Kakoba
|
Uganda |
2023-02-09 11:06:56 |
2026-02-09 |
324 |
15 years and above, female and male wo are on TLD irrespective of tribe |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
|
A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and
antiviral effect of S-217622 compared with placebo in non-hospitalized participants with
COVID-19
REFNo: HS2642ES
The main intent of the study is to evaluate the efficacy of S-217622 vs. placebo. The study will be conducted in the setting of the locally available standard-of-care COVID-19 treatment. High-risk and low-risk participants will be analyzed together for the primary analysis and separately for secondary analyses. The following primary, secondary, and exploratory objectives will be addressed in the modified intent-to-treat (mITT) population, except for the safety analyses, which will be analyzed in the Safety population, and pharmacokinetic (PK) analyses, which will be analyzed in the PK population.
|
Tororo, All Parishes
|
Uganda |
2023-02-06 17:17:04 |
2026-02-06 |
Each site in Uganda will (through competitive enrolment) enroll at least 8 participants making a total of 32 participants for all Uganda sites. |
Outpatient adults (≥18 years) with: a) documented positive
SARS-CoV-2 nucleic acid or antigen test from a sample
collected ≤120 hours (5 days) prior to randomization, b) onset
of symptoms of COVID-19 ≤5 days prior to randomization,
c) presence of 1 or more select COVID-19 symptoms within
24 hours prior to randomization. Participants will be eligible
regardless of vaccination status and will be classified as either
high risk or low risk.
High-risk participants: defined as aged ≥65 years or those with
presence of high-risk conditions.
|
National Institute of Allergy and Infectious Diseases (NIH), Division of AIDS (DAIDS) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Noella Okalany Akwi Regina
ID: UNCST-2022-R011085
|
Congenital Cytomegalovirus Infection in Eastern Uganda
REFNo: HS2668ES
To determine the short-term neurodevelopmental outcomes and hearing impairment associated with congenital cytomegalovirus among infants in Eastern Uganda.,To determine the incidence of, and risk factors for postnatally acquired cytomegalovirus among infants in Eastern Uganda.,To describe the factors associated with congenital cytomegalovirus infection in neonates in Eastern Uganda.,To determine the prevalence of congenital cytomegalovirus infection among neonates in Eastern Uganda,To investigate the burden of congenital cytomegalovirus and its outcomes among infants in Eastern Uganda.,
|
Mbale, Mbale
Budaka, Budaka
|
Uganda |
2023-02-06 16:21:08 |
2026-02-06 |
2000 |
0 - 6 months of age |
University of Liverpool |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
